Part B Competitive Acquisition: CMS Bows To Pressure On ASP Exemption
Executive Summary
Bowing to a major demand of both vendors and physicians, the Centers for Medicare & Medicaid Services will exempt Part B competitive acquisition program drug prices from average sales price calculations, at least for the first three years of the CAP
You may also be interested in...
AmerisourceBergen May Become CAP Vendor, But Oncology Is A Tough Sell
AmerisourceBergen is weighing whether to bid to become a vendor for Medicare Part B's competitive acquisition program (CAP)
AmerisourceBergen May Become CAP Vendor, But Oncology Is A Tough Sell
AmerisourceBergen is weighing whether to bid to become a vendor for Medicare Part B's competitive acquisition program (CAP)
Rethinking CAP: Medicare Suspends Bidding Due To Vendor Unease
Concerns expressed by potential drug distributors for the Medicare Part B competitive acquisition program (CAP) apparently triggered the Centers for Medicare & Medicaid Services' decision to place the bidding process on hold